United States· US:63323-597_723278d4-d701-4b94-a615-ac07a1305e2d

Deferoxamine

A deferoxamine product containing deferoxamine mesylate, registered in United States by Fresenius Kabi USA, LLC. The same ATC class is registered in 16 of our 19 countries.

ATC V03AC01

Checked against FDA National Drug Code directory (United States) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about deferoxamine mesylateAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Deferoxamine is registered in 16 of 19 countries.

Countries holding a registration under ATC V03AC01 (deferoxamine), each read from that country’s own register.

This record: United States, from FDA National Drug Code directory (United States)
10 of them publish a price we can compare per daily dose

Search deferoxamine products by name

Deferoxamine · ATC V03AC01

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of deferoxamine costs, country by country.

Normalised to the WHO defined daily dose (2.8 g), so markets compare like for like.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Deferoxamine · price per daily dose (2.8 g)

USD · FX 28 Sept 2026

CH Switzerland$48.38
FR France$33.66

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)

Active substance: DEFEROXAMINE MESYLATE
Manufacturer: Fresenius Kabi USA, LLC
Country: United States (US)
ATC code: V03AC01
ATC class: Deferoxamine
Defined daily dose: 2.8 g, P
Reimbursed: Not published by this register
Source register: FDA National Drug Code directory (United States)
Last checked: September 27, 2026

Packs & prices · 1

ndc11
63323-597-10

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

49 interactions on record for deferoxamine.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check deferoxamine against other medicines How interaction checks work

Deferoxamine · interactions on record

49 records

9 severe
5 moderate
35 info

Most severe, free to view

CidofovirJ05AB12severe
VigabatrinN03AG04severe
InotersenN07XX15severe
IopamidolV08AB04severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Deferoxamine in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deferoxamine products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

Austria · Desferal
Belgium · Desferal
Bulgaria · Десферал
Cyprus · Deferoxamine Noridem
Czechia · Desferal
Germany · Deferoxaminmesilat Noridem Enterprises, Desferal
Denmark · Desferal
Spain · Desferin
Finland · Desferal
France · Desferal
United Kingdom (Northern Ireland) · Desferrioxamine Mesilate Noridem Enterprises
Greece · Deferoxamine Noridem, Demoferidon
Hungary · Desferal
Ireland · Desferal
Iceland · Desferal
Italy · Deferoxamina Noridem, Desferal
Luxembourg · Desferal
Netherlands · Desferal
Norway · Desferal
Poland · Desferal
Portugal · Desferal
Romania · Desferal
Sweden · Desferal

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/701f7a6d-a36b-40bc-8985-95dc71be4bb2
GET /v1/drugs/701f7a6d-a36b-40bc-8985-95dc71be4bb2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS",
  "source": "ndc",
  "strength": "95",
  "substance": "DEFEROXAMINE MESYLATE",
  "productndc": "63323-597",
  "dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
  "dea_schedule": null,
  "strength_unit": "mg/mL",
  "application_number": "ANDA078718",
  "marketing_category": "ANDA"
}

API reference MCP server Plans

See everything about deferoxamine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console